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Abstract
Objective This article reviews the different technical aspects
and pitfalls of gadolinium (Gd)-ethoxibenzyl (EOB)-dieth-
ylenetriamine pentaacetic acid (DTPA) and the advantages
of the hepatocellular phase (HCP) and defines its specific
imaging features of liver lesions.
Background Gd-EOB-DTPA is a contrast agent with com-
bined properties of a conventional non-specific extracellular
and a hepatocyte-specific contrast agent. Benign cirrhosis-
associated nodules are characterised by isointensity in dy-
namic imaging and the HCP. Hepatocellular carcinomas
(HCCs) usually show hyperenhancement in the arterial
phase, with washout in the portal vein pressure (PVP) and
hypointensity in the HCP. Among other characteristic find-
ings, we have the mosaic pattern, a capsule, the “nodule-in-
nodule” appearance and the satellite nodules. The fibrola-
mellar HCC is a large enhancing heterogeneous lesion, on a
non-cirrhotic liver, with a hypointense scar in every se-
quence. THIDs (transient hepatic intensity differences) are
perfusional alterations, characterised by hyperintensity in
the arterial phase, with no alterations in the rest of the
sequences including the HCP. Adenoma and focal nodular
hyperplasia (FNH) are lesions, occurring more frequently in
young women, with brisk arterial enhancement, differenti-
ated by the scar and the uptake of Gd-EOB-DTPA in the
HCP. Focal eosinophilic infiltration is a difficult diagnosis,
with characteristics such as a non-spherical shape and irreg-
ular borders suggesting it. Besides these lesions, in which
Gd-EOB-DTPA has a clear advantage, there are a few where
the specificities of this agent can be troublesome: haeman-
giomas, focal fat/sparing, foreign body reaction, cholangio-
carcinoma and metastases.
Conclusion Gd-EOB-DTPA is comparable to extracellular
agents, and uptake by functioning hepatocytes in the
delayed phase provides additional information that further
improves detection and characterisation of many hepatic
lesions.
Main Messages
• Gd-EOB-DTPA offers advantages for the imaging of
many liver lesions including HCC, fibrolamellar HCC,
FNH and adenoma.
• The properties of Gd-EOB-DTPA can pose problems
when dealing with haemangiomas, cholangiocarcinoma
and metastases among others.
• The uptake of Gd-EOB-DTPA by functioning hepatocytes
in the delayed phase provides additional information that
further improves detection and characterisation of many
hepatic lesions.
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Introduction
Hepatocyte-specific magnetic resonance (MR) imaging con-
trast agents were developed for detection and characterisation
of focal liver lesions. Currently, there are two hepatocyte-
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specific agents available: gadolinium (Gd)-ethoxibenzyl
(EOB)-diethylenetriamine pentaacetic acid (DTPA) and
gadobenate dimeglumine (Gd-BOPTA). Gd-EOB-DTPA has
greater hepatocellular uptake and biliary excretion than Gd-
BOTPA and is the focus of this review.
Gd-EOB-DTPA—known generically as gadoxetic acid
and commercially as Eovist (United States) or Primovist
(most parts of the World) (Bayer Healthcare)—is a highly
water-soluble contrast agent in which a lipophilic EOB
group is attached to gadolinium (Gd)-DTPA (Fig. 1). The
resulting compound has properties of a conventional non-
specific extracellular contrast agent in the vascular phases
after administration, permitting assessment of tissue vascu-
larity, and those of a hepatocyte-specific agent in the more
delayed phases, allowing assessment of hepatocellular up-
take and biliary excretion [1, 2]. Due to the presence of the
lipophilic EOB group, Gd-EOB-DTPA is actively trans-
ported from the sinusoidal space into hepatocytes via organ-
ic anion transporting polypeptides (OATPs). Entry of the
contrast agent into liver cells causes intense parenchymal
enhancement, beginning within 1 or 2 min of contrast agent
injection. The enhancement peaks at around 20 min and lasts
for at least 2 h. The agent is excreted from hepatocytes into
the biliary canaliculi via multidrug resistance-associated pro-
teins (MRPs) [3, 4]. Excretion into the bile ducts causes
biliary luminal enhancement, as early as 5-10 min after
injection in normal individuals. It is eliminated in approxi-
mately equal proportions by the liver, via hepatocellular
uptake with subsequent biliary excretion (43.1–53.2%), and
by the kidneys (41.6–51.2%) [5, 6].
Gd-EOB-DTPA has been shown to be comparable to
non-specific extracellular agents for lesion detection and
characterisation in the vascular imaging phases. Moreover,
uptake by functioning hepatocytes in the delayed phase
provides additional information that further improves detec-
tion and characterisation of many hepatic lesions, reported
in recent articles [7, 8]. The purpose of this review is to
illustrate the typical appearance of focal hepatic lesions with
MRI and to understand the advantages, pitfalls and differ-
ential diagnosis using Gd-EOB-DTPA. The lesions are thus
divided into those for which Gd-EOB-DTPA demonstrates
advantages, those in which have pitfalls and those in which
the lesion behaviour is equivalent to that of the use of an
extracellular fluid (ECF) contrast agent.
General considerations
The vascular imaging phases using Gd-EOB-DTPA are sim-
ilar to those using extracellular agents with a few caveats:
1. Arterial phase enhancement of vessels and lesions with
Gd-EOB-DTPA tends to be less intense than with extra-
cellular agents due to the following factors. Gd-EOB-
DTPA is administered in a smaller dose than extracellular
agents (0.025 mmol/kg), providing a shorter temporal
window to acquire images during peak arterial enhance-
ment. Additionally, there is a higher frequency of imaging
artefacts in the arterial phase when compared with extra-
cellular agents. The cause of these artefacts is not well
understood. These “truncation” artefacts may occur due to
abrupt concentration changes during high spatial k-space
filling, and may alter the intensity, shape and anatomical
detail of the structures.
2. Hepatocellular uptake begins almost immediately, leading
to rapidly progressive liver enhancement. Consequently,
there is no pure venous or equilibrium phase. Because the
liver enhances sooner and more intensely than with ex-
tracellular agents, the intensity of the lesions relative to
the liver may appear different. For example, blood vessels
and blood-pool lesions, such as haemangiomas, which
remain hyperintense in comparison to the liver during
all vascular phases with extracellular agents, appear to
“wash out” with Gd-EOB-DTPA and, after 5-10 min,
become hypointense.
3. The degree of hepatocellular enhancement depends on
liver function, which roughly correlates with serum bili-
rubin levels, which is not a perfect predictor. In livers with
good hepatic function, intense enhancement occurs. In
livers without good function, due to cholestasis or hepa-
tocellular dysfunction, enhancement of liver parenchyma
may be weak. In such cases, blood vessels and blood pool
lesions become isointense rather than hypointense in
comparison to the liver.
Focal hepatic lesions
Lesions in which Gd-EOB-DTPA provides advantages
Cirrhosis-related nodules
1. Regenerative and dysplastic nodules
Overview: Cirrhosis is pathologically defined by ex-
tensive fibrosis, nodular regeneration and architectural
distortion of the parenchyma. The vast majority of
cirrhosis-related nodules exhibit regenerative changes
without cellular atypia and are known as regenerative
nodules (RNs). A minority have dysplastic features andFig. 1 Molecular structure of Gd-EOB-DTPA
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are known as dysplastic nodules (DNs). The differenti-
ation between RN and DN is unreliable when attempted
non-invasively, difficult with histopathology, and is of
minor, if any, clinical relevance. For these reasons, these
two entities are discussed together as benign cirrhosis-
associated nodules.
Unenhanced MRI features: Typically, benign cirrhosis-
associated nodules are <2 cm and isointense to hyperin-
tense on T1-weighted images, isointense to hypointense on
T2-weighted images and isointense on diffusion-weighted
(DW) images. Lipid-containing nodules or steatotic nod-
ules display signal loss on out-of-phase gradient echo
(GRE) images in comparison with in-phase images. Iron-
containing nodules or siderotic nodules appear markedly
hypointense on T2-weighted and T2*-weighted images
(Fig. 2).
Dynamic imaging with extracellular contrast agent:
After the injection of the contrast, most benign cirrhosis
associated-nodules show similar enhancement to the adja-
cent liver in the arterial and venous phases [9, 10]. Some
benign cirrhosis associated-nodules enhance in the arterial
phase and typically fade to isointensity in the venous
phases.
Imaging with Gd-EOB-DTPA: Uptake and excretion of
gadobenate dimeglumine by these nodules is usually pre-
served. Consequently, they are usually isointense in the
hepatocellular phase (HCP) [11].
Differential diagnosis: The diagnosis of most benign
cirrhosis-associated nodules is straightforward with MRI,
using extracellular agents. However, some benign cirrhosis
associated-nodules may show enhancement in the arterial
phase. These hypervascular benign nodules usually fade to
isointensity in the venous phases. While most cirrhosis-
associated nodules with arterial phase hyperenhancement
and venous phase isoenhancement are benign, small hepa-
tocellular carcinomas (HCCs) can have a similar appear-
ance. Nodules with arterial phase hyperenhancement and
venous phase isoenhancement can therefore cause diagnos-
tic confusion and lead to inappropriatemanagement. Use of
Gd-EOB-DTPA can be helpful in the differential diagnosis
of these lesions. Homogeneous isointensity in the HCP
relative to liver suggests benignancy: routine follow-up is
sufficient. By comparison, hypointensity in the HCP sug-
gests malignancy: such lesions require biopsy, empirical
treatment or close follow-up depending on lesion size and
clinical considerations.
Potential pitfalls: Siderotic and steatotic nodules may
appear hypointense in the HCP, potentially mimicking
early HCC. This is due to the iron and fat content being
already of low signal intensity in the pre-contrast fat satu-
rated sequences. Some benign nodules may appear hyper-
intense in the HCP [14] (Fig. 3). The mechanism is still
unknown, but overexpression of organic anionic transport-
er peptides (OATP) or down-regulation of MDRs could
possibly play a role. Such lesionsmay bemistaken for focal
nodular hyperplasia (FNH)-like lesions (these are also
Fig. 2 A benign cirrhosis-associated nodule in a 38-year-old woman
with chronic liver disease. a Pre-contrast MRI, b, c arterial phase, d PV
phase, e delayed phase, f hepatocellular phase. The image shows a liver
with a lobulated contour and a nodular parenchyma (cirrhosis). The
solid arrows point to a small rounded focal lesion, markedly hypoin-
tense in all sequences (more conspicuous with the increase of the TE),
showing no enhancement with the contrast agent. The curved arrow
points to multiple Gamna-gandy bodies (hemosiderin deposition)
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benign, so the distinction is irrelevant) or atypical HCCs
with HCP hyperintensity. The differentiation between be-
nign andmalignant HCP-hyperintense nodules is discussed
in the following two sections. Small benign cirrhosis-
associated nodules with arterial-phase hyperenhancement
and HCP hypointensity may be indistinguishable from
small HCCs.
2. Acquired FNH-like lesions
Overview: These lesions are described in cirrhotic liv-
ers, and are macroscopically, microscopically and immu-
nohistochemically identical to classic FNH seen in non-
cirrhotic livers. They are believed to originate from ac-
quired hyperplastic responses to vascular alterations asso-
ciated with cirrhosis, as opposed to conventional FNHs,
which are believed to originate from developmental
responses to congenital arterio-vascular malformations.
Unenhanced MRI features: Hypointense to isointense
on T1-weighted MR images and mildly hyperintense to
isointense on T2-weighted images. The “central scar”, if
present, is hyperintense on T2-weighted images.
Dynamic imaging with extracellular contrast agent:
These lesions usually show intense enhancement in the
arterial phase and fade to isointensity in the portal venous
and later phases. Rarely, they may reveal a slight washout
in the PV phase; marked washout is incompatible with
FNH. [12].
Imaging with Gd-EOB-DTPA: Usually it enhances in
the hepatobiliary phase (Fig. 4), but there have been reports
of a few cases revealing hepatobiliary hypointensity [13].
Differential diagnosis: The major differential diagno-
sis is HCC, especially for small lesions with less than
3 cm, those without a central scar and those with HCP
hypointensity.
Potential pitfalls: While HCP hyperintensity is
characteristic of FNH-like lesions, this finding is non-
specific and may also be observed in HCCs (see be-
low). Favouring the diagnosis of a FNH-like lesion is
the presence of a central scar and/or a network of
fibrous septa carving the nodule into smaller lobules.
Favouring HCC are the mosaic architecture, presence
of a tumour capsule, mildly hyperintense signal inten-
sity of T2-weighted, restricted diffusion on DW images
or a combination of these.
While most FNH-like lesions exhibit diffuse HCP
hyperintensity, these lesions may have central zones of
portal venous phase washout and HCP hypointensity,
mimicking HCC. In equivocal cases, close follow-up
or biopsy should be considered (depending on lesion
size and other factors).
Hepatocellular carcinoma
Overview HCC is the most common primary malignant he-
patic tumour. Underlying cirrhosis from viral hepatitis (B and
C), alcoholism, non-alcoholic steatohepatitis (NASH) and
toxin exposure are the predominant causal factors. Tumour
markers, such as serum-fetoprotein or PIVKA-II, are usually
elevated in patients with HCC [14, 15].
Fig. 3 A benign cirrhosis-
associated nodule in a 39-year-
old man with chronic liver dis-
ease. Gd-EOB-DTPA enhanced
MRI. a arterial phase, b PV
phase, c delayed phase, d
5 min, e 10 min, f hepatocellu-
lar phase. The image shows a
liver with a nodular contour and
a heterogeneous parenchyma.
The arrows point to a small
rounded focal lesion accumu-
lating Gd-EOB-DTPA- benign
nodule
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However, elevation of tumour markers does not help
determine which of several lesions is malignant, if multiple
nodules are observed, and negative tumour markers do not
exclude HCC.
Unenhanced MRI features On T1-weighted MR images,
HCC is most often hypointense relative to the liver, although
hyperintense lesions or areas of hyperintensity within hypo-
intense lesions may be seen [15]. On T2-weighted images,
HCC is generally hyperintense, although some well-
differentiated HCC may be seen as isointense or mildly hypo-
intense lesions. Steatotic HCCs are characterised by a signal
loss on out-of-phase images relative to in-phase images
(Fig. 5). Haemorrhagic hepatocellular carcinomas may have
marked high signal intensity on T1-weighted images and low
signal intensity on T2- and T2*-weighted images.
Dynamic imaging with extracellular contrast agent Typi-
cally, HCCs (80%) show intense enhancement in the arterial
phase contrast-enhanced images, with washout in the portal
venous phase (Fig. 6). Less than 20% of the HCCs
are hypovascular (usually well-differentiated tumours) [15,
16]. Small HCCs (most commonly well differentiated
HCCs) are usually homogeneous. Large HCCs (most com-
monly moderately or poorly differentiated) may exhibit a
broad spectrum of morphologic features, including a mosaic
pattern (Fig. 7), a tumour capsule, an intratumoural nodule
(“nodule-in-nodule” appearance), and an extracapsular
extension with the formation of satellite nodules. A tumour
capsule shows higher enhancement than that of the sur-
rounding parenchyma on delayed phase images. Capsular
disruption, with extracapsular extension or absence of a
capsule, is associated with poorer prognosis.
Imaging with Gd-EOB-DTPA In the hepatocellular phase,
HCCs usually show low signal intensity. The degree and
homogeneity of hypointensity is variable, depending on the
concentration and function of cellular membrane receptors
and transporters (OATPs and multidrug resistance-associated
proteins [MRPs]). In some (2.5-8.5%), uptake of the contrast
agent can paradoxically occur (Fig. 8). Most of these hyper-
intense HCCs are well or moderately differentiated, with bile-
producing or bile-containing capacity maintained [17–20].
Differential diagnosis Cholangiocarcinoma, arterioportal
(AP) shunt, atypical haemangioma and hepatic adenoma
are possible diagnosis. The usual occurrence in a cirrhotic
liver, in addition to the dynamic and hepatocelullar phase
imaging, usually permit the differential diagnosis.
Potential pitfalls Some HCCs will uptake Gd-EOB-DTPA
in the hepatobiliary phase. These can usually be differenti-
ated from RN, DN and FNH-like lesions because of their
heterogeneity or mosaic pattern, the nodule-in-nodule ap-
pearance, the presence of a hypoenhancing rim (capsule) or
the absence of a scar.
Fig. 4 An FNH-like lesion in a 41-year-old man with chronic liver
disease. a Pre-contrast MRI, b arterial phase, c PV phase, d 5 min, e
10 min, f hepatocellular phase. The image shows a liver with a
lobulated contour. The arrows point to a small rounded focal lesion,
isointense in the Pre-contrast sequence, showing brisk arterial enhance-
ment. In the HCP it accumulates Gd-EOB-DTPA, exposing the typical
FNH internal architecture
Insights Imaging (2012) 3:451–474 455
Infiltrative HCC may manifest as subtle heterogeneity and
mild ill-defined hypointensity in the HCP. This may mimic
background cirrhotic parenchyma and escape detection.
Fibrolamellar HCC
Overview Fibrolamellar HCC is an uncommon type of HCC
affecting young adults.
Unenhanced MRI features It is usually seen as a large, well-
circumscribed focal lesion with low signal intensity on T1-
weightedMR images and high signal intensity on T2-weighted
images. A central radiating scar is seen in 80% of cases and has
low signal intensity on T1- and T2-weighted images. Areas of
liquefactive necrosis may occur centrally and appear markedly
hyperintense on T2-weighted images.
Dynamic imaging with extracellular contrast agent There is
usually early heterogeneous contrast enhancement, which
fades on subsequent images. The scar has minimal or no
enhancement on contrast-enhanced images, being usually
hypointense relative to the remainder of the tumour (Fig. 9).
Fig. 6 Hypervascular HCCs in a 50-year-old man with chronic liver
disease. a Pre-contrast MRI, b arterial phase, c portal vein pressure
(PVP), d 3 min, f 4 min, f HCP. Marked heterogeneous liver with
nodular contour, with reticulation in the HCP- cirrhotic The arrows
point to two rounded focal lesions, with arterial enhancement (one less
prominent), PV washout and hypointensity in the HCP
Fig. 5 Fatty HCC in a 45-year-old man with chronic liver disease. a
Pre-contrast MRI, b, c arterial phase, d 3 min, f 4 min, f 8 min, g IP,
h OP, i SSFSE, j b0, k b500, l T1-weighted PDFF. The arrows point to
a rounded focal lesion, with arterial enhancement, PV washout and
hypointensity in the HCP. It also shows heterogeneous loss of signal in
OP (fat), expressed likewise in the fat fraction map as bright areas in
the lesion
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Imaging with Gd-EOB-DTPA In hepatocellular phase some
viable areas of the tumour may show some uptake of Gd-
EOB-DTPA. The scar remains hypointense [21].
Differential diagnosis Hypointensity of the scar on T2-
weighted images and the hypointensity in the HCP
distinguish fibrolamellar HCC from a FNH. It can be distin-
guished from HCC due to the presence of a scar, calcifica-
tions, larger size and occurrence in younger patients with
no cirrhosis.
Potential pitfalls The absence of a scar and the uptake of
Gd-EOB-DTPA in the HCP may be confounders.
Nodular perfusional alterations versus wedge-shaped per-
fusional alterations (transient hepatic intensity differences
[THIDs])
Overview These perfusional alterations are phenomenon
characterised by a patchy wedge-shaped area of enhance-
ment involving a hepatic subsegment or by an arterial en-
hancing focal lesion that fades in the venous phase.
Unenhanced MRI features Generally, there are no altera-
tions in morphology or signal intensity.
Dynamic imaging with extracellular contrast agent This
finding is seen immediately after contrast material administra-
tion, with fading on subsequent images. They are thought to
represent an imbalance between the hepatic arterial and portal
venous supply, caused by increased hepatic arterial blood flow
in the presence of portal vein obstruction (Figs. 10 and 11).
Typically, transiently increased segmental perfusion enhance-
ment indicates that the portal venous supply is compromised
due to compression or thrombosis.
Imaging with Gd-EOB-DTPA No alterations in the hepato-
biliary phase, due to intact hepatocyte function of these lesions,
make it possible to differentiate from small HCCs [22, 23].
Fig. 7 A 52-year-old man with chronic liver disease. a Arterial phase,
b HCP. Imaging findings of a cirrhotic liver, with a lesion (large
arrows) with areas of enhancement (thin arrow) and non-enhancing
areas—mosaic pattern. In the HCP we found a similar appearance with
areas taking up Gd-EOB-DTPA and others not
Fig. 8 HCC in a 42-year-old woman with chronic liver disease. a Pre-contrast MRI, b arterial phase, c PV phase, d 5 min, e 10 min, f HCP.
Hypervascular HCC, with washout in the PV phase and uptake of Gd-EOB-DTPA (arrows)
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Differential diagnosis Small HCCs and hypervascular me-
tastases are possible diagnosis. Usually the absence of a
defect in the HCP makes the diagnosis of THID.
Potential pitfalls Rarely, vascular alterations are associated
with dysfunction of the hepatocytes, which reveal a defect in
the HCP, complicating the diagnosis.
Focal nodular hyperplasia (FNH)
Overview FNH is the secondmost common benign tumour of
the liver, after hepatic haemangiomas. FNH typically occurs
as a solitary lesion in young female patients. It consists of
aggregates of hepatocytes and is thought to be secondary to a
proliferative response of hepatocytes, secondary to an under-
lying vascular malformation. Biliary structures proliferate
without connection to the adjacent biliary tree. Kupffer cells
are present, often in greater amounts than in the surrounding
normal liver parenchyma. The central scar in FNH is not a true
scar, but represents a congeries of blood vessels, bile ducts and
sometimes a focal area of cirrhosis. About 20% of FNH cases
are classified as non-classic. These non-classic FNH subtypes
lack the findings of nodular architecture or malformed vessels
but always have bile duct proliferation.
Unenhanced MRI features The lesion varies from mildly
hypointense to isointense on T1-weighted MR images and
from mildly hyperintense to isointense on T2-weighted
images. The “central scar” is characteristically hyperintense
on T2-weighted images. The hyperintensity of the lesion on
T2-weighted images may be related to the presence of
vascular channels or oedema throughout the lesion.
Fig. 9 Fibrolamellar-HCC in a
34-year-old man without liver
disease. a Pre-contrast MRI, b
arterial phase, c PV phase, d
HCP. Big nodular lesion in the
left lobe isointense in pre-
contrast imaging, with arterial
enhancement, washout in the
PV phase and no uptake of Gd-
EOB-DTPA in the HCP (thick
arrow). The central scar (thin
arrow) remains hypointense in
all sequences
Fig. 10 THIDs in a 38-year-old man with chronic liver disease. a Pre-contrast MRI, b arterial phase, c 2 min, d 3 min, e IP, f OP, g T2, h DWI
B500. Heterogeneous liver with nodular contour. Fluffy hyperintense areas in the arterial phase (arrows), not seen in the other sequences
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Dynamic imaging with extracellular contrast agent FNH is
perfused by the hepatic arterial system and shows marked,
nearly uniform arterial-phase enhancement. The degree of
lesion enhancement lessens on subsequent contrast-enhanced
images, with lesion signal intensity approaching that of the
surrounding liver parenchyma. The central scar has low signal
intensity on early phase contrast-enhanced images but gradu-
ally enhances to become hyperintense relative to the rest of the
lesion on delayed phase images [24, 25]. The capsule is
usually absent.
Imaging with Gd-EOB-DTPA With hepatobiliary-specific
agents, it shows homogenous or heterogeneous enhance-
ment in the hepatocellular phase, as it lacks a well-formed
bile canalicular system for normal excretion. It becomes
isointense to hyperintense to the normal liver, allowing
the differential diagnosis [8, 26]. More than the enhance-
ment itself, the hepatocellular phase also permits the
evaluation of the internal architecture (reticulation or
lace-like appearance), which provides more certainty in
the diagnosis (Fig. 12).
Differential diagnosis Adenoma and fibrolamellar HCC.
The isointensity to hyperintensity in the HCP and the imag-
ing features of the central scar of FNH are usually helpful in
the differential diagnosis. The adenoma does not present a
central scar and is hypointense in the HCP. The F-HCC is
usually larger, more heterogeneous and its scar is hypoin-
tense in every sequence.
Also, the non-classic forms often present a diagnostic
challenge in imaging: e.g. telangiectatic FNH has been
shown to demonstrate atypical imaging features, including
lack of a central scar, high signal intensity on T1- and T2-
weighted images and persistent enhancement on delayed
phase images [26].
Potential pitfalls About 12% of FNH can show atypical
imaging features on Gd-EOB-DTPA enhanced MRI, such
as the absence of a scar or an eccentric one, or washout in
the venous phase.
Adenoma
Overview Hepatic adenomas are rare benign tumours of the
liver. On histopathological analysis, hepatic adenomas contain
well-differentiated hepatocytes lacking bile ducts or portal tracts.
The majority of adenomas are solitary (80%) and typically occur
in female patients (90%). Predisposing factors to adenoma for-
mation include oral contraceptive use in female patients, anabolic
steroid use in male patients and glycogen storage disease [27].
Unenhanced MRI features They are generally well circum-
scribed, without contour lobulation and have variable
degrees of haemorrhage, necrosis, fat and, rarely, calcifica-
tion. At MR imaging, adenomas are typically hyperintense
to isointense on T1-weighted images and slightly hyperin-
tense on T2-weighted images.
Dynamic imaging with extracellular contrast agent After
administration of contrast material, adenomas typically
demonstrate moderate enhancement on arterial phase
images; they may show washout and enhancement similar
to that of surrounding liver parenchyma on portal venous
and delayed phase images [28].
Fig. 11 Multiple THIDs and a
big HCC in a 47-year-old man
with chronic liver disease. a
Pre-contrast MRI, b arterial
phase, c PV phase, d delayed
phase. Big nodular lesion in the
left lobe hypointense in pre-
contrast imaging, with arterial
enhancement, internal arteries,
washout in the PV phase and
heterogeneous uptake of Gd-
EOB-DTPA in the HCP (*).
There also seen multiple nodu-
lariform hyperintense areas in
the arterial phase (arrows), not
seen in the other sequences—
THIDs
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Imaging with Gd-EOB-DTPA Usually no enhancement of he-
patic adenoma is seen in the hepatocellular phase because of
absent or strongly reduced hepatocellular uptake of Gd-EOB-
DTPA (Fig. 13). However, peripheral or faint diffuse enhance-
ment has been reported in some cases due to some hepatocytes
maintaining the capability of uptake and excretion in the HCP.
Fig. 12 FNH in a 37-year-old woman with no liver disease. a Pre-
contrast MRI, b, c arterial phase, d 3 min, e 5 min, f 8 min, g 10 min,
h HCP. Big nodular lesion (thick arrows), with lobulated contours
isointense in pre-contrast imaging, with arterial enhancement, washout
in the PV phase and uptake of Gd-EOB-DTPA in the HCP—note the
fine reticular architecture typical of a FNH. The central scar (thin
arrow) remains hypointense in all sequences
Fig. 13 Liver adenoma in a 35-year-old woman on oral contracep-
tives, with no liver disease. a Pre-contrast MRI, b, c arterial phase, d
3 min, e 5 min, f HCP. Lobulated lesion in the right lobe isointense in
pre-contrast imaging, with arterial enhancement, internal arteries and
no uptake of Gd-EOB-DTPA in the HCP (arrow)
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Differential diagnosis FNH and HCC.
The age and gender of the patient, occurring in a non-
cirrhotic liver (as opposed to HCC), the absence of a scar or
the enhancement pattern, usually helps in the diagnosis,
since FNH is isointense to hyperintense in the HCP, while
the adenoma is typically hypointense.
Potential pitfalls The adenoma may show faint enhance-
ment in the HCP, which is a confounder, but the other
imaging characteristics usually permit the diagnosis.
Focal hypereosinophilic infiltration (FEI)
Overview FEI of the liver is a focal hepatic lesion caused by
eosinophil-related tissue damage. It is associated with vari-
ous eosinophilia-related conditions such as parasitic infec-
tions, allergic reactions, hypereosinophilic syndrome and
tumours.
Unenhanced MRI features They have an indistinct margin
and a non-spherical shape [29, 30]. On T1- and T2-weighted
images, visible focal eosinophilic infiltrations and eosino-
philic abscesses exhibit low and high signal intensities,
respectively.
Dynamic imaging with extracellular contrast agent The
dynamic imaging is characterised by poor enhancement on
the arterial phase with homogeneous enhancement on portal
venous phase images.
Imaging with Gd-EOB-DTPA They show mixed hypointen-
sity, irregular margins and non-spherical shapes in hepato-
cellular phase (Fig. 14).
Differential diagnosis Metastases and abscesses. The non-
spherical shape and irregular margins favour FEI.
Potential pitfalls The differential diagnosis frommetastases in
a patient with known primary malignancy is still challenging.
Confluent fibrosis
Overview Focal fibrosis occurs in the process of hepatic
parenchyma collapse and its replacement with focal fibrotic
masses, in the context of cirrhosis. It is usually located in the
anterior and medial segments of the liver and has a wedge-
shaped appearance. In some patients the entire segment is
involved.
Unenhanced MRI features Fibrosis can appear as an area of
low signal intensity on T1-weighted MR images and high
signal intensity on T2-weighted images. It shows a typical
geographic pattern of involvement, associated to retraction
of the liver capsule.
Dynamic imaging with extracellular contrast agent It
usually demonstrates delayed enhancement on contrast-
enhanced images.
Imaging with Gd-EOB-DTPA It shows low signal intensity
due to decreased hepatic function from fibrosis (Fig. 15).
Differential diagnosis Infiltrative HCC and cholangiocarci-
noma. Confluent fibrosis can be differentiated from infiltra-
tive tumours on the basis of typical geographic appearance,




nodule in a 55-year-old man
with no liver disease. a Arterial
phase, b PV phase, c HCP, d
T2-weighted. Small non-
spherical lesion with ill-defined
margins in the right lobe with
poor enhancement in the arterial
and PV phase, mixed hypoin-
tensity on the HCP and slightly
hyperintense in T2-weighted
(black arrows). This lesion was
biopsy proven to be a lesion of
focal eosinophilic infiltration
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Potential pitfalls Contrary to delayed enhancement of fibro-
sis on gadolinium-enhanced MRI, confluent hepatic fibrosis
demonstrates hypointense areas due to decreased or absent
hepatocellular uptake of Gd-EOB-DTPA.
Lesions in which Gd-EOB-DTPA has pitfalls and thus
requires careful interpretation
Cavernous haemangioma
Overview Cavernous haemangiomas represent the most
common primary liver tumour and consist of multiple
large, blood-filled vascular channels. Typically, haeman-
giomas are solitary, although multiplicity is not uncom-
mon. Although they are typically small, giant cavernous
haemangiomas may range in size (greater than 20 cm).
Haemangiomas are associated with several clinical syn-
dromes including Klippel-Trenaunay-Weber syndrome,
Osler-Rendu-Weber disease, and von Hippel–Lindau
disease.
Unenhanced MRI features On MR imaging, hepatic hae-
mangiomas typically demonstrate low signal intensity on
T1-weighted images and marked high signal intensity on
T2-weighted images.
Dynamic imaging with extracellular contrast agent On en-
hanced MRI, there is a typical peripheral nodular enhance-
ment with centripetal progression, resulting in diffuse high
signal intensity on delayed phase images. Less commonly,
flash filling of an entire small haemangioma or enhancement
of small portions of the lesion, on arterial phase images, may
be seen. Larger lesions may not demonstrate uniform en-
hancement on delayed phase images, probably due to areas
of thrombosis or insufficient delay time. Central scars may
be seen in hepatic haemangiomas.
Imaging with Gd-EOB-DTPA With this contrast, the en-
hancement of a haemangioma tends to follow the blood
vessels. Hepatic haemangiomas will “pseudo washout” to
become darker than the liver because of rapid uptake of the
contrast agent by the surrounding normal liver during equi-
librium phase (Fig. 16). However, careful analysis usually
permits differential diagnosis from malignant lesions that
washout, as malignant lesions will washout more rapidly
than the vessels, while haemangiomas will parallel the
vessels [31].
Differential diagnosis Small haemangioma may mimic
hypervascular metastasis. In these cases, the bright signal
of haemangiomas in heavily T2-weighted sequences is
Fig. 15 Confluent fibrosis in a 56-year-old man with cirrhosis. a Pre-
contrast, b, c arterial phase, d PV phase, e 3 min, f 5 min, g 8 min,
h HCP. Wedge-shaped ill-defined areas associated with capsular
retraction, with decreased enhancement in the dynamic phases and
with no uptake of Gd-EOB-DTPA in the HCP (arrows)
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Fig. 17 Focal fat sparing area and a FNH, in a 36-year-old woman
with no liver disease. a OP, b IP, c PDFF, d T2-weighted, e T1 fat-sat, f
arterial phase, g PV phase, h HCP. Triangular-shaped periportal area
(arrows) hyperintense to the rest of the liver in OP and Fat Sat imaging
mimicking uptake of Gd-EOB-DTPA, corresponding to a fat spared
area. This is confirmed in the fat-fraction map. Of note, is a lesion (*)
compatible with a FNH
Fig. 16 Haemangioma in a 39-year-old woman with no liver disease.
a, b Arterial phase, c PV phase, d 3 min, e 5 min, f HCP. Right lobe
hypointense lesion with arterial nodular peripherical enhancement (thin
arrow) with centripetal progression. Note that the hepatocellular
uptake starts immediately (curved arrow). The intralesional enhance-
ment follows the blood pool. In the HCP the lesion is hypointense
because of rapid uptake of Gd-EOB-DTPA by the surrounding normal
liver during equilibrium phase (thick arrow)
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Fig. 19 Multiple hypervascular metastases, in a 39-year-old woman
with breast cancer. a Pre-contrast, b arterial phase, c PVP, d 3 min, e
5 min, f HCP. Multiple nodular lesions are seen, hyperenhancing in the
arterial phase, with washout in the PVP, some with a hypointense
necrotic centre (solid arrow). In the HCP, some of these lesions
paradoxically uptake Gd-EOB-DTPA in the necrotic centre (thin
arrow)
Fig. 18 Cholangiocarcinoma with a satellite lesion, in a 62-year-old
man. a Pre-contrast, b, c arterial, d 3 min, e 5 min, f HCP. Large mass-
forming lesion, irregular contour, with mild heterogeneous enhance-
ment in the dynamic phases, with no uptake of Gd-EOB-DTPA in the
HCP (thick arrow) There is another lesion (thin arrow) in the left lobe
with similar contrast uptake proprieties and a necrotic centre, compat-
ible with a metastasis
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helpful. Furthermore, in the dynamic phases, the intralesional
degree of enhancement is similar to that of the adjacent
vessels, pointing to a lesion filling with less enhanced blood
due to the uptake of the hepatocytes.
Potential pitfalls In patients with prolonged intravascular
dwell time due to hepatic or renal insufficiency, haemangio-
mas may appear isointense to the liver in the hepatocellular
phase rather than hypointense. The key is parallelism to the
blood pool.
Focal fat/focal sparing
Overview Focal fatty deposition and focal fatty sparing
may manifest as a “pseudolesion”. Clues to this diagnosis
are its more common occurrence in the following areas of
the liver: the medial aspect of the left lobe, along the
falciform ligament, round the gallbladder fossa and within
the central aspect of segment IV, adjacent to the porta
hepatis. In addition, focal fatty infiltration is not seen to
exert mass effect and vessels are seen to pass through these
areas unimpeded.
Unenhanced MRI features MR imaging provides a useful
method for characterising suspected geographic fatty infil-
tration by using in-phase and opposed-phase gradient-echo
T1-weighted sequences. The relative increase in intravoxel
fat in areas of focal fatty infiltration demonstrates decreased
signal intensity on the opposed-phase images in comparison to
the in-phase images. On MR imaging, areas of fatty sparing
may be identified due to the lack of decrease in signal intensity
on opposed-phase gradient-echo T1-weighted images and
appear hyperintense relative to surrounding steatosis. Focal
fat often appears dark on opposed-phase images, while focal
sparing often appears bright [32].
Dynamic imaging with extracellular contrast agent Focal
fat deposition and fat sparing areas show similar degree of
enhancement to surrounding hepatic parenchyma.
Imaging with Gd-EOB-DTPA Areas of focal fat sparing area
can be shown as mildly increased signal intensity on the
hepatobiliary phase because the signal intensity of the focal
fat sparing area is already higher on the unenhanced fat
saturated sequence (Fig. 17).
Fig. 20 Multiple hypovascular metastases, in a 60-year-old man with
an NE tumour. a Pre-contrast, b, c arterial, d 3 min, e 5 min, f 8 min, g
10 min, h HCP. Multiple hypointense nodular lesions, with no
significant enhancement in the dynamic phases, one of large dimen-
sions in the right lobe (arrows), with progressive central pooling of Gd-
EOB-DTPA, more evident in the HCP
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Differential diagnosis Focal hepatic lesion and lipoma. The
typical locations and the T2 findings usually permit the
diagnosis, since these pseudo-lesions are invisible on that
sequence.
Potential pitfalls Areas of focal fat sparing are enhanced
because they have functional hepatocytes and these can
appear as real focal lesions in the dynamic phases. However,
the other imaging findings described permit the diagnosis.
Intrahepatic cholangiocarcinoma
Overview Cholangiocarcinoma is the most common biliary
tumour and the second most common primary malignant
hepatic tumour in adults. Risk factors for the development
of cholangiocarcinoma include primary sclerosing cholan-
gitis (PSC), familial polyposis, choledochal cyst, biliary
papillomatosis and clonorchiasis.
Unenhanced MRI features Intrahepatic cholangiocarcinoma
may be mass forming or peribiliar infiltrative. They are usually
hypointense on T1-weighted MR images and hyperintense on
T2-weighted images. Associated findings may include adjacent
biliary ductal dilatation, capsular retraction, satellite nodules,
vascular encasement and hepatolithiasis [32–34].
Dynamic imaging with extracellular contrast agent On
contrast-enhanced images, it demonstrates initial peripheral
enhancement with concentric internal filling on delayed-
phase images.
Imaging with Gd-EOB-DTPA Usually no enhancement is seen
in the hepatocellular phase due to lack of hepatocytes (Fig. 18).
Differential diagnosis HCC and cholangitis. The delayed
enhancement and the typical hilar location point to
cholangiocarcinoma.
Potential pitfalls Delayed enhancement of cholangiocarci-
noma is one of the characteristic findings when using extra-
cellular agents, due to its abundant fibrosis. However, the
tumour shows low signal intensity on delayed and hepatobili-
ary phases of Gd-EOB-DTPA, due to strong enhancement of
the surrounding liver parenchyma.
Fig. 21 Foreign body reaction, in a 41-year-old man that suffered a car
accident after a New Year’s dinner. a, b Arterial phase, c PVP, d 5 min, e
8 min, f HCP. In the posterior aspect of the left lobe we see a fluffy
heterogeneous hyperenhancing area, that progressively washes out and gives
origin to a Gd-EOB-DTPA defect (thin arrows). Histologically proven, after
surgery, to be an inflammatory reaction to a small carrot fragment
466 Insights Imaging (2012) 3:451–474
Hypervascular metastases
Overview Islet cell tumours, breast cancer, melanoma, thy-
roid cancer and carcinoid tumour are among the most com-
mon primary tumours that lead to hypervascular hepatic
metastases.
Unenhanced MRI features These metastatic lesions usually
demonstrate low signal intensity on T1-weighted MR
images and are iso to hyperintense on T2-weighted images.
Dynamic imaging with extracellular contrast agent Hyper-
vascular metastases are best seen during the arterial phase of
enhancement. Small hypervascular metastases usually pres-
ent with homogeneous enhancement, whereas larger lesions
appear heterogeneous or show an enhancing peripheral rim
surrounding the necrosis. Frequently, centripetal contrast
enhancement is observed, as well as irregular or peripheral
washout. Hypervascular metastatic lesions may show a tar-
get appearance on delayed phase, with the rim appearing
hypointense relative to the centre. This centripetal progres-
sion of enhancement, with simultaneous peripheral washout,
is specific for malignancy.
Imaging with Gd-EOB-DTPA Generally no enhancement is
seen in the hepatocellular phase.
Differential diagnosis HCC, THID, adenoma and FNH. The
presence of multiple lesions in a non-cirrhotic liver, in a
patient with a known malignancy and a defect on the HCP
point to metastases.
Potential pitfalls In the centre of metastatic lesions, there
may be pooling of Gd-EOB-DTPA in the extracellular ma-
trix of the lesion, giving the misguiding appearance of
uptake in the hepatobiliary phase (Fig. 19).
Fig. 22 Multiple hepatic cysts, in a 47-year-old woman, with no liver
disease. a Pre-contrast, b arterial, c PVP, d 3 min, e 5 min, f 8 min, g
10 min, h HCP. Multiple rounded hypointense lesions (arrows), with
no enhancement during all the phases. These lesions were also mark-
edly hyperintense in T2-weighted imaging (not shown)
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Fig. 24 Pseudolipoma
(Glisson’s capsule lipoma). a IP
b OP c arterial d HCP. Small,
no enhancing peripheral lesion
(arrow), losing internal signal
in OP, indicating the presence
of intracellular fat.
Histologically proven, after
surgery, to be a pseudolipoma
Fig. 23 Angiomyolipoma in a
40-year-old man with a history
of renal lesions. a Arterial
phase, b T2 fat sat, c OP, d IP.
Large mass-forming lesion, ir-
regular contour, with mild het-
erogeneous enhancement in the
arterial phase (arrow). It loses
internal signal in OP, indicating
the presence of intracellular fat
(black arrow). These were his-
tologically proven to be an
angiomyolipoma
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Fig. 26 TP granulomas, in a
42-year-old man with active
pulmonary TP. a Arterial phase,
b PVP, c delayed phase, d HCP.
There are two nodular lesions
(arrows), with faint peripheral
enhancement, that appear as
defects in the HCP, as they have
no hepatocytes to uptake Gd-
EOB-DTPA
Fig. 25 Inflammatory pseudotumour, in a 52-year-old man with PSC. a, b Arterial phase, c PVP, d 3 min, e 5 min, f HCP. Ill-defined hypointense
area, in the right lobe (arrows), seen in the dynamic phases, not visualised in the HCP, proven to represent an inflammatory pseudolesion
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Hypovascular metastases
Overview Colon, lung, prostate, gastric and transitional cell
carcinomas are the most common primary tumours with
hypovascular metastases to the liver.
Unenhanced MRI features These metastatic lesions usual-
ly demonstrate low signal intensity on T1-weighted MR
images and are iso to hyperintense on T2-weighted
images.
Dynamic imaging with extracellular contrast agent The
ring-like enhancement surrounding liver metastases is typ-
ically seen during the hepatic arterial phase. In the portal
and delayed phase, the metastases often show washout in
the outer parts and a progressive enhancement toward the
centre of the lesions (Fig. 20).
Imaging with Gd-EOB-DTPA No enhancement is seen in
the hepatocellular phase.
Differential diagnosis HCC, cholangiocarcinoma and focal
eosinophilic infiltration. Multiple lesions, a known primary
malignant tumour and a non-cirrhotic liver, point to the diag-
nosis. The pattern of enhancement and the spherical shape are
other helpful findings.
Potential pitfalls As mentioned earlier, with Gd-EOB-
DTPA, the differential diagnosis can be difficult.
Foreign body reaction
Overview Various foreign bodies introduced into the human
organism during surgery or trauma, as well as exposure to
some chemical substances, may cause a granulomatous
reaction.
Unenhanced MRI features Imaging features are usually
hypointensity in T1-weighted images and hyperintensity in
T2-weighted images, with possible hypointense bands with-
in the cystic cavity.
Fig. 27 Liver abscess, in a 54-year-old man with history of choledocal
litiasis. a Pre-contrast, b, c arterial, d 3 min, e 5 min, f HCP. On the
posterior aspect of the liver, there is a thick-walled hypointense lesion
(solid arrow), with no internal enhancement during the dynamic
phases. Note the excretion of Gd-EOB-DTPA on the HCP, proving
the connection of this abscess with the biliary tree
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Dynamic imaging with extracellular contrast agent: It
shows peripheral enhancement of the mass on arterial or
portal venous phase.
Imaging with Gd-EOB-DTPA No enhancement is seen in
the hepatocellular phase (Fig. 21).
Differential diagnosis Metastatic disease. It could be con-
sidered in patients with a perihepatic lesion with previous
history of trauma or surgery.
Potential pitfalls A foreign body can gradually move from a
subcapsular to an intraparenchymal position.
Lesions in which the lesion behaviour is equivalent
to that of when using an ECF contrast agent
Focal hepatic lesions that show similar behaviour with
ECF contrast agent and Gd-EOB-DTPA include hepatic
cysts (Fig. 22), biliary hamartomas, biliary cystadenoma
or carcinomas, angiomyolipoma (Fig. 23), lipoma
(Fig. 24), inflammatory pseudotumour (Fig. 25), granu-
lomatous disease (Fig. 26), hepatic abscesses (Fig. 27)
and lymphoma (Fig. 28).
Lesions in which the authors have no experience
The following lesions were never studied with Gd-EOB-
DTPA-enhanced MRI: hematoma, peliosis, paranglioma
and angiosarcoma.
Summary
For a summary, see Tables 1 and 2.









Benign ⇒ ⇒ ⇒ ⇒
Benign ⇑ ⇒ ⇒ ⇒
Benign ⇑ ⇓ ⇓ ⇑
Indeterminate ⇓ ⇓ ⇓ ⇓ or ⇑
Malignant ⇑ ⇓ ⇓ ⇓
Malignant ⇓ ⇑ ⇓ ⇓
Fig. 28 Liver Lymphoma, in a
39-year-old woman. a Pre-
contrast, b arterial phase, c
PVP, d HCP. Large infiltrative
lesion in the right lobe
(arrows), hypointense in the
pre-contrast phase, with faint
heterogeneous arterial enhance-
ment, with washout in the PVP,
not taking up Gd-EOB-DTPA
in the HCP. Note involvement
of the tumour along the peri-
portal route (black arrow) and
right adrenal gland (white
arrows)
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